- Home
- DXST vs GOVX Comparison
DXST vs GOVX Comparison
Compare DXST & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXST
- GOVX
- Stock Information
- Founded
- DXST 2011
- GOVX 2001
- Country
- DXST China
- GOVX United States
- Employees
- DXST N/A
- GOVX N/A
- Industry
- DXST
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- DXST
- GOVX Health Care
- Exchange
- DXST NYSE
- GOVX Nasdaq
- Market Cap
- DXST 21.4M
- GOVX 19.5M
- IPO Year
- DXST 2025
- GOVX N/A
- Fundamental
- Price
- DXST $1.41
- GOVX $1.67
- Analyst Decision
- DXST
- GOVX Strong Buy
- Analyst Count
- DXST 0
- GOVX 5
- Target Price
- DXST N/A
- GOVX $14.20
- AVG Volume (30 Days)
- DXST 366.4K
- GOVX 569.4K
- Earning Date
- DXST 01-01-0001
- GOVX 03-03-2025
- Dividend Yield
- DXST N/A
- GOVX N/A
- EPS Growth
- DXST N/A
- GOVX N/A
- EPS
- DXST N/A
- GOVX N/A
- Revenue
- DXST $4,333,276.00
- GOVX $3,090,161.00
- Revenue This Year
- DXST N/A
- GOVX N/A
- Revenue Next Year
- DXST N/A
- GOVX $150.51
- P/E Ratio
- DXST N/A
- GOVX N/A
- Revenue Growth
- DXST N/A
- GOVX N/A
- 52 Week Low
- DXST $1.21
- GOVX $1.09
- 52 Week High
- DXST $5.74
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- DXST N/A
- GOVX 37.32
- Support Level
- DXST N/A
- GOVX $1.50
- Resistance Level
- DXST N/A
- GOVX $1.79
- Average True Range (ATR)
- DXST 0.00
- GOVX 0.13
- MACD
- DXST 0.00
- GOVX 0.01
- Stochastic Oscillator
- DXST 0.00
- GOVX 29.82
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.